National Bank Of Canada Cassava Sciences Inc Transaction History

National Bank Of Canada

$72.7 Billion
Q3 2024

A detailed history of National Bank Of Canada transactions in Cassava Sciences Inc stock. As of the latest transaction made, National Bank Of Canada holds 95,291 shares of SAVA stock, worth $223,933. This represents 0.0% of its overall portfolio holdings.

Number of Shares

95,291

Previous 95,291 -0.0%

Holding current value

$223,933

Previous $2.8 Million -0.0%

% of portfolio

0.0%

Previous 0.0%

11 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2024 Nov 12, 2024	SELL	$9.57 - $35.08 $1.23 Million - $4.5 Million	-128,309 Reduced 57.38%	95,291 $2.8 Million
Q2 2024 Aug 02, 2024	BUY	$12.35 - $26.11 $2.7 Million - $5.7 Million	218,400 Added 4200.0%	223,600 $2.76 Million
Q1 2024 May 13, 2024	SELL	$18.44 - $26.41 $4.78 Million - $6.84 Million	-259,110 Reduced 98.03%	5,200 $105,000
Q4 2023 Feb 06, 2024	BUY	$12.64 - $30.11 $1.87 Million - $4.46 Million	148,000 Added 127.25%	264,310 $5.95 Million
Q3 2023 Oct 10, 2023	BUY	$16.64 - $25.32 $1.93 Million - $2.93 Million	115,700 Added 18967.21%	116,310 $1.94 Million
Q1 2023 Apr 12, 2023	SELL	$23.46 - $36.44 $1,173 - $1,822	-50 Reduced 7.58%	610 $14,000
Q4 2022 Jan 24, 2023	SELL	$27.82 - $44.16 $550,836 - $874,367	-19,800 Reduced 96.77%	660 $0
Q3 2022 Oct 13, 2022	BUY	$16.33 - $51.06 $329,621 - $1.03 Million	20,185 Added 7340.0%	20,460 $855,000
Q2 2022 Jul 28, 2022	SELL	$17.22 - $38.47 $2.03 Million - $4.53 Million	-117,835 Reduced 99.77%	275 $8,000
Q1 2022 May 05, 2022	SELL	$32.6 - $53.05 $2.42 Million - $3.94 Million	-74,230 Reduced 38.59%	118,110 $4.39 Million
Q4 2021 Jan 24, 2022	BUY	$36.77 - $90.91 $7.07 Million - $17.5 Million	192,340 New	192,340 $8.41 Million

Others Institutions Holding SAVA

# of Institutions

207

Shares Held

14M

Call Options Held

2.98M

Put Options Held

6.57M

View Full List

About CASSAVA SCIENCES INC

Ticker SAVA
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 40,097,900
Market Cap $94.2M
Description
Cassava Sciences, Inc., a clinical stage biotechnology company, develops drugs for neurodegenerative diseases. Its lead therapeutic product candidate is simufilam, a small molecule drug, which is completed Phase 2b clinical trial; and investigational diagnostic product candidate is SavaDx, a blood-based biomarker/diagnostic to detect Alzheimer's...

More about SAVA

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of National Bank Of Canada , based on Form 13F filings with the SEC.

News

Stay updated on National Bank Of Canada with notifications on news.

Account

National Bank Of Canada Cassava Sciences Inc Transaction History